This study looks at how well a drug called AZD6234 works and how safe it is for adults who are overweight or have obesity. It focuses on those with extra weight-related health issues, with or without Type 2 Diabetes Mellitus (T2DM). Participants will be randomly placed in groups to receive either AZD6234 or a placebo (a fake treatment) alongside their current incretin-based therapy, which is a type of diabetes medication that helps control blood sugar.
The study lasts 68 weeks and measures weight loss. **Phase III** means it's a later stage of testing to check if the drug is effective and safe. **Double-blind** means neither the participants nor the researchers know who is receiving the drug or placebo, ensuring unbiased results.
- The study lasts 68 weeks, with multiple visits required.
- Participants will receive either AZD6234 or a placebo.
- Potential side effects or risks will be monitored during the study.
How understandable was the trial content above?
Hard to understand
Easy to understand